For example, Wang et al. reported the use of autologous CD133 targeted CAR-T cells in Phase-I trial, completed in 23 patients with late-stage metastasis malignancies (14 with hepatocellular carcinoma, 7 with pancreatic carcinomas, and 2 with colorectal carcinomas). Here, PROM1 is linked to hepatocellular carcinoma.